Aoxing Pharmaceutical Company, Inc.

Aoxing Pharmaceutical Company, Inc.

OOTC:AOXG
0.00
USD
0.00
(0.00%)
-0.02EPS
30.67MMarket Cap

Total Valuation

USD

As of March 31, 2017, Aoxing Pharmaceutical Company, Inc. carries a market capitalization of 30.67M, placing it among publicly traded companies globally. Its enterprise value stands at 50.29M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap30.67M
Enterprise Value50.29M

Share Statistics

As of March 31, 2017, Aoxing Pharmaceutical Company, Inc. has 76.21M shares outstanding.

Shares Outstanding76.21M

Valuation Ratios

These figures are as of March 31, 2017. The price-to-sales ratio is 1.02, and the price-to-book ratio stands at 1.60.

PS Ratio1.02
PB Ratio1.60
P/TBV Ratio1.77
P/FCF Ratio-22.00
P/OCF Ratio-22.49

Enterprise Valuation

As of March 31, 2017, Aoxing Pharmaceutical Company, Inc. trades at an EV/EBITDA multiple of 25.74 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.67 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 51.99 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 50.29M versus a market cap of 30.67M, with the gap driven by net debt and cash on the balance sheet.

EV / Sales1.67
EV / EBITDA25.74
EV / EBIT51.99

Financial Position

As of March 31, 2017, Aoxing Pharmaceutical Company, Inc. maintains a current ratio of 0.79, meaning it holds 0.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 153.29, indicating elevated leverage, while an interest coverage ratio of 3.05 demonstrates adequate ability to service its debt obligations.

Current Ratio0.79
Quick Ratio0.51
Debt / Equity153.29
Debt / EBITDA14.19
Interest Coverage3.05

Financial Efficiency

USD

Over the twelve months ended March 31, 2017, Aoxing Pharmaceutical Company, Inc. posted a negative return on equity (ROE) of -7.20, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -2.41, reflecting losses generated across the asset base. The company generates approximately 87,009.58 in revenue per employee across its workforce of 346.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.32 indicates how many times Aoxing Pharmaceutical Company, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)-7.20
Return on Assets (ROA)-2.41
Revenue Per Employee87,009.58
Employee Count346.00
Inventory Turnover2.32

Taxes

USD

Over the twelve months ended March 31, 2017, Aoxing Pharmaceutical Company, Inc. recorded an income tax benefit of -408,979.00 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -1.87M and -1.46M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax-408,979.00

Stock Price Statistics

USD

As of the close on November 16, 2026, Aoxing Pharmaceutical Company, Inc.'s stock has declined approximately 30.30% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.01.

52-Week Price Change-30.30%
200-Day Moving Average0.01

Income Statement

USD

Over the twelve months ended March 31, 2017, Aoxing Pharmaceutical Company, Inc. generated 30.11M in revenue and converted that into -1.46M in net income, yielding earnings per share of -0.02. EBITDA reached 1.95M, while operating income came in at 967,218.00.

Revenue30.11M
Gross Profit22.94M
Operating Income967,218.00
Pretax Income-1.87M
Net Income-1.46M
EBITDA1.95M
EBIT967,217.00
Earnings Per Share (EPS)-0.02

Balance Sheet

USD

As of March 31, 2017, Aoxing Pharmaceutical Company, Inc. holds 7.08M in cash and equivalents against 27.72M in total debt, resulting in a net debt position of 20.64M. Total book value stands at 19.11M, with working capital of -9.17M providing operational flexibility.

Cash & Cash Equivalents7.08M
Total Debt27.72M
Net Debt20.64M
Equity (Book Value)19.11M
Book Value Per Share0.25
Working Capital-9.17M

Cash Flow

USD

Aoxing Pharmaceutical Company, Inc. produced -1.36M in operating cash flow over the twelve months ended March 31, 2017. After subtracting -30,267.00 in capital expenditures, free cash flow totaled -1.39M - equivalent to -0.02 per share.

Operating Cash Flow-1.36M
Capital Expenditures-30,267.00
Free Cash Flow-1.39M
FCF Per Share-0.02

Margins

Over the twelve months ended March 31, 2017, Aoxing Pharmaceutical Company, Inc. posted a gross margin of 76.19, reflecting its pricing power and cost economics. The operating margin of 3.21 and net profit margin of -4.86 provide insight into operational efficiency.

Gross Margin76.19
Operating Margin3.21
Pretax Margin-6.21
Profit Margin-4.86
EBITDA Margin6.49

Dividends & Yields

These figures cover the twelve months ended March 31, 2017. Free cash flow yield is negative at -4.55: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -9.33, meaning Aoxing Pharmaceutical Company, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-9.33
FCF Yield-4.55

Stock Splits

Aoxing Pharmaceutical Company, Inc.'s most recent stock split took place on March 29, 2010 with a 2:1 split ratio.

Last Split Date3/29/2010
Split Ratio2:1

Scores

As of March 31, 2017, Aoxing Pharmaceutical Company, Inc. has an Altman Z-Score of -0.51, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-0.51